Laboratorio Avi-Mex, S.A. de C.V. Company Profile

Background

Laboratorio Avi-Mex, S.A. de C.V., commonly known as Avimex®, is a privately held Mexican company established in 1952. The company specializes in the research, development, manufacturing, import, export, and commercialization of biological and pharmaceutical products aimed at enhancing animal health. Avimex® offers a diverse range of products, including vaccines, pharmaceuticals, disinfectants, and mycotoxin detoxifiers, primarily targeting the poultry, swine, cattle, and aquaculture industries.

Mission: To promote animal health and food safety, enhancing the competitiveness and success of our clients.

Vision: To be a cutting-edge, bio-innovative company, leading in Mexico and with a global presence, recognized for our business ethics.

Purpose: To support food security with quality animal protein for human well-being.

Key Strategic Focus

Avimex® focuses on:

Core Objectives: Enhancing animal health and productivity through innovative solutions.

Specializations: Development of vaccines and pharmaceuticals for various animal species.

Key Technologies: Utilization of advanced biotechnology and bio-innovation in product development.

Primary Markets: Mexico and over 30 countries across Africa, Asia, Central America, South America, Eastern Europe, and the Middle East.

Financials and Funding

Specific financial details, including total funds raised and recent funding rounds, are not publicly disclosed. However, Avimex® has demonstrated financial resilience, with an estimated annual revenue of approximately $14.7 million USD. The company has also received support from the Mexican government, such as a grant of 467,311 MXN under the INNOVATEC program in 2014.

Pipeline Development

Avimex® is actively involved in the development of veterinary vaccines, including those targeting avian influenza and COVID-19. The company has been working on a recombinant Newcastle disease virus (rNDV) vaccine platform for COVID-19, aiming to provide a safe and effective solution for animal health.

Technological Platform and Innovation

Avimex® distinguishes itself through:

Proprietary Technologies: Development of recombinant vaccines and bio-innovative solutions.

Scientific Methods: Application of molecular biology techniques in vaccine development.

AI-Driven Capabilities: Integration of advanced technologies to enhance product efficacy and safety.

Leadership Team

Key executives include:

Juan Agustin Torres Islas

Perla Prieto

MVZ Carlos Garbuno Guerra

Iris Gonzalez

Specific roles and professional backgrounds are not publicly detailed.

Competitor Profile

Market Insights and Dynamics

The animal health industry is experiencing growth due to increased demand for animal protein and advancements in veterinary medicine. Companies like Zoetis and Elanco are significant players in this sector.

Competitor Analysis

Zoetis: A global leader in animal health, specializing in vaccines and pharmaceuticals.

Elanco: Focuses on animal health products, including vaccines and therapeutics.

Strategic Collaborations and Partnerships

Avimex® collaborates with various institutions and organizations to enhance its research and development capabilities, although specific partnerships are not publicly detailed.

Operational Insights

Avimex® maintains a competitive edge through its focus on bio-innovation, quality standards, and a diverse product portfolio tailored to the needs of the animal health industry.

Strategic Opportunities and Future Directions

The company aims to expand its global presence, particularly in emerging markets, and continues to invest in research and development to address evolving challenges in animal health.